Asian markets are mostly lower on Tuesday due to cautious trading amid uncertainty over US trade policies.

Despite positive European market cues, investors are waiting for clear signals. The recent decision by US President Trump to delay tariffs on US goods has added to the uncertainty.

US markets were closed on Monday for the Memorial Day holiday followed by decline on Friday, after US President Trump announced plans to impose 50% tariff on imports from European Union starting from 1 June 2025.

Here's a table showing how US stocks performed on Friday:

Source: Equitymaster

At present, the BSE Sensex is trading 664 points lower, and the NSE Nifty is trading 201 points lower.

IndusInd Bank is among the top gainers today

Ultratech Cement, Axis Bank, M&M, on the other hand, are among the top losers today.

The BSE MidCap index ended 0.1% lower, and the BSE SmallCap index ended 0.1% higher.

Sectoral indices were trading mixed today, with stocks in realty sector and industrial sector witness buying. Meanwhile, stocks banking sector and services sector witnessing selling pressure.
 

Aurobindo Pharma Q4 Revenue Decline

Aurobindo Pharma's net profit declined slightly by 0.5% to Rs 9.03 billion (bn) in Q4FY25 compared to Rs 9.07 bn in the same quarter last year.

Revenue from operation rose 10.6% to Rs 8.4 bn driven by the growth in the key business segments.

Revenue growth in key markets, with US formulation rising 13.5% to Rs 4.1 bn and Europe formulations increasing 17.2% to Rs 2.2 bn.

Revenue from Growth markets dropped 7.8% to Rs 0.7 bn due to weaker performance in some regions.

Also, antiretroviral (ARV) revenue rising 29.4% to Rs 0.3 bn and Active Pharmaceutical Ingredient (API) revenue increasing 5% to Rs 1.1 bn.

The company's EBITDA before R&D stood at Rs 2.2 bn with a margin of 26.3% while EBITDA before forex and other income was Rs 1.8 bn with a margin of 21.4%.

The company spent Rs 0.4 bn on R&D, which is 5% of total revenue. It also received final approval for 5 ANDAs from the UFSDA during the quarter.

Domestic formulation sales were 0.5 bn, while API revenue rose 0.7% to Rs 1.1 bn and ARV revenue rose 24.1% to Rs 0.3 bn.
 

Dabur India Approves Sesa Care Merger

Dabur India approved merging Sesa Care into the company, pending approval from shareholders, creditors, and regulators.

Dabur is merging with Sesa because it is well-known ayurvedic brand, ranking third in hair oil, which will strengthen Dabur's product lineup.

The merger aims to boost Dabur's presence in hair care, expand Sesa's reach and leverage Dabur's expertise and supply chain to drive growth in the hair oil segment.

It will also combine resources, creating synergies in finance, management, tech, distribution, and marketing. Benefits like better cash management, improved efficiency, and access to more funds for growth and development.

Dabur is India's top FMCG company, specializing in Ayurvedic and natural healthcare products with global distribution.

Bajaj Healthcare Post Q4 Profit Surge

Bajaj Healthcare made a profit of Rs 0.1 bn in Q4, compared to a loss of Rs 0.3 bn in the same quarter last year.

Revenue rose 15.4% to Rs 1.5 bn from Rs 1.3 bn last year.

Profit before tax stood Rs 0.1 compared to a loss of Rs 0.3 bn in the same period last year.

Bajaj Healthcare posted yearly profit of Rs 0.4 bn compared to a loss of Rs 0.8 bn last year.

Bajaj Healthcare founded in 1993, produces Active Pharmaceutical Ingredients and Formulations.

Also, it is first Indian company to get government approval for processing opium derived substances.

More By This Author: